Acquisition - November 8, 2018
Novo Nordisk expands its biopharm business
The compay has made an agreement to acquire the US and Canadian rights to Macrilen (macimorelin), an enhancer of growth hormone secretion and the first and only FDA-approved oral product indicated for the diagnosis of Adult Growth Hormone Deficiency (AGHD), a rare endocrine disorder, from Strongbridge Biopharma Plc. Macrilen was approved by the FDA in December […]
Acquisition - November 6, 2018
AstraZeneca sells drug rights to Covis Pharma for up to $371 million
The company has entered into an agreement with Covis Pharma B.V. to sell its rights to the medicines Alvesco (ciclesonide), usedfor the treatment of persistent asthma, and Omnaris and Zetonna (ciclesonide), used for the treatment of nasal symptoms associated with rhinitis. The rights cover markets outside the US and the US royalties for the medicines. Covis Pharma currently commercialises Alvesco, […]
Acquisition - October 30, 2018
EQT announces a public cash offer to the shareholders in Karo Pharma AB
Yesterday EQT, through Fund VIII Swe Bidco AB, under name change to Karo Intressenter AB, has announced a public cash offer to the shareholders in Karo Pharma AB regarding acquisition of all shares in the company. Venture capital company EQT’s offer for Karo Pharma is 36.9 SEK per share, they state in a press release. The total value […]
Acquisition - September 26, 2018
LINK Medical acquires PCG Clinical Services
LINK Medical Research, based in Oslo, has acquired all shares in PCG Clinical Services, located in Uppsala. After this acquisition, LINK Medical as a group has more than 160 employees in Norway, Sweden, Denmark and Germany, reports the company. “PCG Clinical Services completes our span of offerings within clinical contract research. Thus, we have a […]
Acquisition - August 31, 2018
Ultimovacs acquires Immuneed’s immunotherapy tech business for NOK 50 million
The Norwegian biotech company Ultimovacs took over the immunotherapy technology business of the Swedish company Immuneed AB last month. The complementary technologies of the two companies provide a platform for development of novel vaccine solutions for treatment and possibly prevention of cancer, reports Ultimovacs. The acquired business has been named Ultimovacs AB and is now a […]
Acquisition - August 22, 2018
Novo Nordisk acquires Ziylo for 800 million USD
Novo Nordisk has acquired all of the shares of Ziylo, a University of Bristol spin-out company based at Unit DX science incubator in Bristol, UK. The acquisition gives Novo Nordisk full rights to Ziylo’s glucose binding molecule platform to develop glucose responsive insulins. Ziylo’s glucose binding molecules are synthetic molecules that were designed by Professor Anthony […]
